Phaseline

Companies › Partner Therapeutics

Partner Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zenocutuzumab (MCLA-128)
ErbB-2/ErbB-3 heterodimer inhibitor
ERBB2, ERBB3Phase 2Solid Tumours Harboring NRG1 FusionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02912949Zenocutuzumab (MCLA-128)Phase 2Solid Tumours Harboring NRG1 FusionOncologyDec 2026

Targets

ERBB2 (1) ERBB3 (1)

Companies with the same targets

Beijing Biotech Roche Shanghai Institute Of Biological Products Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Daiichi Sankyo Pfizer Merck & Co. (MSD) Sichuan Baili Pharmaceutical

Companies built like this

Ambrx Abscint NV/SA Aston Sci. Chengdu SciMount Pharmatech SystImmune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.